share_log

Cidara Therapeutics Analyst Ratings

Cidara Therapeutics Analyst Ratings

西达拉治疗分析师评级
Benzinga ·  2023/11/06 06:35
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/06/2023 631.71% HC Wainwright & Co. → $6 Reiterates Buy → Buy
09/22/2023 265.85% Needham → $3 Reiterates Buy → Buy
09/22/2023 631.71% HC Wainwright & Co. → $6 Reiterates Buy → Buy
09/08/2023 265.85% Needham → $3 Reiterates Buy → Buy
09/07/2023 631.71% HC Wainwright & Co. → $6 Reiterates Buy → Buy
08/07/2023 631.71% HC Wainwright & Co. → $6 Reiterates → Buy
08/04/2023 265.85% Needham → $3 Reiterates Buy → Buy
08/01/2023 631.71% HC Wainwright & Co. → $6 Reiterates → Buy
08/01/2023 509.76% Cantor Fitzgerald → $5 Reiterates Overweight → Overweight
06/26/2023 631.71% HC Wainwright & Co. → $6 Reiterates Buy → Buy
05/15/2023 631.71% HC Wainwright & Co. → $6 Reiterates Buy → Buy
05/12/2023 265.85% Needham → $3 Reiterates Buy → Buy
04/18/2023 265.85% Needham → $3 Reiterates → Buy
03/24/2023 631.71% HC Wainwright & Co. → $6 Reiterates → Buy
03/23/2023 631.71% HC Wainwright & Co. $6.5 → $6 Maintains Buy
03/08/2023 509.76% Cantor Fitzgerald → $5 Reiterates → Overweight
03/01/2023 692.68% HC Wainwright & Co. → $6.5 Reiterates → Buy
01/25/2023 692.68% HC Wainwright & Co. $6 → $6.5 Maintains Buy
05/12/2022 631.71% HC Wainwright & Co. $7.5 → $6 Maintains Buy
09/22/2021 875.61% Aegis Capital $9 → $8 Maintains Buy
09/22/2021 — WBB Securities Upgrades Buy → Strong Buy
03/04/2021 997.56% Aegis Capital → $9 Initiates Coverage On → Buy
08/26/2020 509.76% Citigroup $6 → $5 Maintains Buy
03/05/2020 631.71% Needham $10 → $6 Maintains Buy
12/04/2019 662.2% WBB Securities → $6.25 Upgrades Speculative Buy → Buy
09/04/2019 — Wedbush Upgrades Neutral → Outperform
06/06/2019 631.71% Oppenheimer → $6 Initiates Coverage On → Outperform
05/17/2019 143.9% Wedbush $7 → $2 Downgrades Outperform → Neutral
03/01/2019 753.66% Wedbush $12 → $7 Maintains Outperform
日期 上行/下行 分析公司 目标价格变动 评级变动 之前/当前的评级
11/06/2023 631.71% HC Wainwright & Co. → 6 美元 重申 购买 → 购买
09/22/2023 265.85% 尼德姆 → 3 美元 重申 购买 → 购买
09/22/2023 631.71% HC Wainwright & Co. → 6 美元 重申 购买 → 购买
09/08/2023 265.85% 尼德姆 → 3 美元 重申 购买 → 购买
09/07/2023 631.71% HC Wainwright & Co. → 6 美元 重申 购买 → 购买
08/07/2023 631.71% HC Wainwright & Co. → 6 美元 重申 → 购买
08/04/2023 265.85% 尼德姆 → 3 美元 重申 购买 → 购买
08/01/2023 631.71% HC Wainwright & Co. → 6 美元 重申 → 购买
08/01/2023 509.76% 坎托·菲茨杰拉德 → 5 美元 重申 超重 → 超重
06/26/2023 631.71% HC Wainwright & Co. → 6 美元 重申 购买 → 购买
05/15/2023 631.71% HC Wainwright & Co. → 6 美元 重申 购买 → 购买
05/12/2023 265.85% 尼德姆 → 3 美元 重申 购买 → 购买
04/18/2023 265.85% 尼德姆 → 3 美元 重申 → 购买
2023 年 3 月 24 日 631.71% HC Wainwright & Co. → 6 美元 重申 → 购买
03/23/2023 631.71% HC Wainwright & Co. 6.5 美元 → 6 美元 维护 买
03/08/2023 509.76% 坎托·菲茨杰拉德 → 5 美元 重申 → 超重
03/01/2023 692.68% HC Wainwright & Co. → 6.5 美元 重申 → 购买
01/25/2023 692.68% HC Wainwright & Co. 6 美元 → 6.5 美元 维护 买
05/12/2022 631.71% HC Wainwright & Co. 7.5 美元 → 6 美元 维护 买
2021 年 9 月 22 日 875.61% 宙斯盾资本 9 美元 → 8 美元 维护 买
2021 年 9 月 22 日 — WBB 证券 升级 买入 → 强势买入
2021 年 4 月 3 日 997.56% 宙斯盾资本 → 9 美元 启动覆盖范围开启 → 购买
08/26/2020 509.76% 花旗集团 6 美元 → 5 美元 维护 买
03/05/2020 631.71% 尼德姆 10 美元 → 6 美元 维护 买
2019 年 4 月 12 日 662.2% WBB 证券 → 6.25 美元 升级 投机性买入 → 买入
09/04/2019 — Wedbush 升级 中性 → 跑赢大盘
2019 年 6 月 6 日 631.71% 奥本海默 → 6 美元 启动覆盖范围开启 → 跑赢大盘
05/17/2019 143.9% Wedbush 7 美元 → 2 美元 降级 跑赢大盘 → 中性
03/01/2019 753.66% Wedbush 12 美元 → 7 美元 维护 跑赢大盘

What is the target price for Cidara Therapeutics (CDTX)?

Cidara Therapeutics（CDTX）的目标价格是多少？

The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $6.00 expecting CDTX to rise to within 12 months (a possible 631.71% upside). 18 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 于2023年11月6日公布了Cidara Therapeutics（纳斯达克股票代码：CDTX）的最新目标股价。该分析公司将目标股价定为6.00美元，预计CDTX将在12个月内升至12个月内（可能上涨631.71％）。去年有18家分析公司公布了评级。

What is the most recent analyst rating for Cidara Therapeutics (CDTX)?

分析师对Cidara Therapeutics（CDTX）的最新评级是多少？

The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics reiterated their buy rating.

HC Wainwright & Co. 对Cidara Therapeutics（纳斯达克股票代码：CDTX）的最新分析师评级由HC Wainwright & Co. 提供，Cidara Therapeutics重申了买入评级。

When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?

Cidara Therapeutics（CDTX）的下一个分析师评级何时公布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Cidara Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Cidara Therapeutics的最新评级是在2023年11月6日公布的，因此您应该预计下一个评级将在2024年11月6日左右公布。

Is the Analyst Rating Cidara Therapeutics (CDTX) correct?

分析师对 Cidara Therapeutics (CDTX) 的评级正确吗？

While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Cidara Therapeutics (CDTX) is trading at is $0.82, which is within the analyst's predicted range.

尽管评级是主观的，并且会发生变化，但重申了最新的Cidara Therapeutics（CDTX）评级，目标股价为0.00美元至6.00美元。Cidara Therapeutics（CDTX）目前的交易价格为0.82美元，在分析师的预测区间内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发